KilgourMD Phase II Trial Shows Hair Regrowth in Menopausal Women with Androgenetic Alopecia

KilgourMD announced results from an independent, four-month phase II clinical trial evaluating the KilgourMD System composed of the Prevention and Treatment Serums in 43 menopausal-aged women experiencing androgenetic alopecia—an underserved population historically excluded from hair loss research and treatment validation studies. The study found clinically meaningful regrowth in record time, alongside validated reductions in hair shedding.

By day 120, results showed that 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, a threshold dermatologists consider a meaningful visual change, while 26% showed a full one grade improvement. This level of improvement is comparable to — and in some cases exceeds — results typically reported after six to twelve months of conventional pharmaceutical therapies such as minoxidil or finasteride. Across the full study population, participants experienced an average 11.1% improvement in Ludwig score within just four months, underscoring the system's ability to drive measurable regrowth in a significantly shorter timeframe.

Standardized combing and washing assessments revealed a 60% reduction in hair shedding by month four, indicating rapid normalization of the hair growth cycle and improved follicular health. These reductions were observed as early as day 45, when greater than 95% of the trial participants demonstrated a decrease from baseline in terminal hair shedding count, as measured by standardized hair washing studies in the lab.

Unlike many prior studies in the category, eligibility required a clinically significant level of hair loss, ensuring results reflected true therapeutic impact, and the outcome measures were objective and dermatologist-evaluated, rather than the consumer perception studies typically used by cosmetic brands. Regrowth outcomes were graded by two independent board-certified dermatologists, with high-resolution imaging confirming visible improvements in hair density and scalp coverage over time.

Consumer-reported outcomes reinforced the clinical findings: more than 80% of participants reported noticeable improvements in hair density, health, and overall appearance by the end of the study.

The company's founder stated that menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning. The study validates not only the performance of the KilgourMD System, but also the importance of designing and testing solutions specifically for this population.

The full results are currently undergoing peer review and are expected to be published later this year.